|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.20 USD | -0.10% |
|
-0.44% | +11.88% |
| 02-13 | Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM | |
| 02-13 | European Commission approves Amgen's Uplizna® for generalized myasthenia gravis | RE |
| Capitalization | 197B 166B 152B 145B 269B 17,865B 278B 1,762B 701B 8,607B 740B 724B 30,059B | P/E ratio 2025 |
23x | P/E ratio 2026 * | 24.7x |
|---|---|---|---|---|---|
| Enterprise value | 242B 204B 186B 177B 330B 21,900B 341B 2,159B 859B 10,551B 907B 888B 36,848B | EV / Sales 2025 |
6.03x | EV / Sales 2026 * | 6.25x |
| Free-Float |
99.85% | Yield 2025 * |
2.61% | Yield 2026 * | 2.74% |
Last Transcript: Amgen Inc.
| 1 day | -0.10% | ||
| 1 week | -0.44% | ||
| Current month | +7.11% | ||
| 1 month | +12.49% | ||
| 3 months | +8.90% | ||
| 6 months | +28.50% | ||
| Current year | +11.88% |
| 1 week | 361 |  | 384.62 |
| 1 month | 321.71 | | 385.12 |
| Current year | 318.21 | | 385.12 |
| 1 year | 261.43 | | 385.12 |
| 3 years | 211.71 | | 385.12 |
| 5 years | 198.64 | | 385.12 |
| 10 years | 133.64 | | 385.12 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 63 | 01/05/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 67 | 01/01/2020 |
Esteban Santos
COO | Chief Operating Officer | 59 | 25/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 63 | 01/01/2013 |
Tyler Jacks
BRD | Director/Board Member | 65 | 01/01/2012 |
Robert Eckert
BRD | Director/Board Member | 71 | 01/01/2012 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.29% | 5.08% | 136 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.10% | -0.44% | +24.11% | +51.01% | 197B | |
| +2.27% | +1.71% | +18.94% | +200.84% | 930B | |
| +1.53% | +2.84% | +57.51% | +50.82% | 589B | |
| +2.99% | +3.87% | +17.88% | +49.62% | 402B | |
| +0.46% | +1.21% | +21.12% | +29.19% | 374B | |
| +1.31% | +6.82% | +25.93% | +31.90% | 315B | |
| +0.71% | +3.85% | +27.41% | +54.91% | 307B | |
| -0.06% | -0.43% | +39.19% | +9.83% | 296B | |
| +1.88% | +5.75% | -44.79% | -37.12% | 216B | |
| -2.56% | +1.63% | +46.95% | +75.10% | 188B | |
| Average | +0.28% | +3.02% | +23.42% | +51.61% | 381.47B | |
| Weighted average by Cap. | +0.35% | +2.77% | +25.86% | +76.94% |
| 2025 | 2026 * | |
|---|---|---|
| Net sales | 36.34B 30.62B 27.95B 26.67B 49.53B 3,292B 51.23B 325B 129B 1,586B 136B 133B 5,539B | 37.84B 31.89B 29.1B 27.78B 51.58B 3,428B 53.35B 338B 134B 1,652B 142B 139B 5,768B |
| Net income | 7.2B 6.07B 5.54B 5.29B 9.82B 652B 10.15B 64.33B 25.58B 314B 27.01B 26.45B 1,098B | 7.82B 6.59B 6.01B 5.74B 10.66B 708B 11.02B 69.86B 27.78B 341B 29.33B 28.73B 1,192B |
| Net Debt | 44.53B 37.53B 34.25B 32.69B 60.71B 4,035B 62.78B 398B 158B 1,944B 167B 164B 6,789B | 39.27B 33.1B 30.2B 28.83B 53.54B 3,558B 55.37B 351B 140B 1,714B 147B 144B 5,987B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 12/02/26 | 366.20 $ | -0.10% | 2,374,457 |
| 11/02/26 | 366.58 $ | +0.53% | 2,826,184 |
| 10/02/26 | 364.65 $ | -2.97% | 3,526,589 |
| 09/02/26 | 375.82 $ | -2.21% | 2,844,017 |
| 06/02/26 | 384.32 $ | +4.49% | 3,840,306 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition